Study summary
Immunotherapy after surgery did not prevent liver cancer from coming back
What was tested
Pembrolizumab for 1 year, against placebo, after surgery or ablation that left no visible liver cancer, to try to prevent relapse.
What they found
- Median time without relapse was about 46.7 vs 45.5 months, not a significant difference.
- No treatment-related deaths and no new safety signals.
What it means
Shows a drug effective in advanced disease does not automatically work to prevent relapse after surgery; different approaches are needed there.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.